- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06306014
Оценка EXL01, нового живого биотерапевтического продукта для предотвращения рецидива инфекции Clostridioides difficile у пациентов из группы высокого риска (LIVEDIFF)
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.
Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.
In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes.
Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical efficacy preventing recurrence of CDI in 69% to 89% of cases at 8 weeks post-treatment, with a good safety profile.
Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.
The aim of this Phase I/II trial is to assess the efficacy and safety of oral administration of EXL01, a single isolated unmodified strain of F. prausnitzii, in preventing CDI recurrence in high-risk patients at W8. The study will be conducted in 2 parts. The phase I (Part A) is planned to include 6 patients. The phase II (Part B) will include 50 patients in two arms (25 patients respectively in the placebo and EXL01 arm).
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Nicolas BENECH, MD
- Номер телефона: +33 04 26 10 94 35
- Электронная почта: nicolas.benech@chu-lyon.fr
Учебное резервное копирование контактов
- Имя: Fanny JOUBERT
- Номер телефона: +33 04 26 73 27 27
- Электронная почта: Fanny.joubert@chu-lyon.fr
Места учебы
-
-
-
Annecy, Франция
- Еще не набирают
- CH Annecy Genevois Service de Maladies infectieuses
-
Контакт:
- Emilie PIET, MD
- Номер телефона: +33 450636602
- Электронная почта: epiet@ch-annecygenevois.fr
-
Главный следователь:
- Emilie PIET, MD
-
Clermont-Ferrand, Франция, 63003
- Рекрутинг
- Service d'hépato-gastroentérologie - CHU Estaing
-
Контакт:
- Julien SCANZI, MD
- Номер телефона: 04 73 75 02 35
- Электронная почта: jscanzi@chu-clermontferrand.fr
-
Главный следователь:
- Julien SCANZI, MD
-
Grenoble, Франция
- Рекрутинг
- CHU Grenoble Service Maladies infectieuses et tropicales
-
Контакт:
- Salomé GALLET, MD
- Номер телефона: +33 476763947
- Электронная почта: sgallet@chu-grenoble.fr
-
Главный следователь:
- Salomé GALLET, MD
-
Lille, Франция
- Рекрутинг
- CHU Lille Unité des Maladies Infectieuses et tropicales
-
Контакт:
- Sarah STABLER, MD
- Номер телефона: +33 320445743
- Электронная почта: sarah.stabler@chu-lille.fr
-
Главный следователь:
- Sarah STABLER, MD
-
Lyon, Франция, 69004
- Рекрутинг
- Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse
-
Контакт:
- Nicolas BENECH, MD
- Номер телефона: +33 04 26 10 94 35
- Электронная почта: nicolas.benech@chu-lyon.fr
-
Главный следователь:
- Nicolas BENECH, MD
-
Контакт:
- Emma SANDOZ
- Номер телефона: +33 04 26 73 28 62
- Электронная почта: emma.sandoz@chu-lyon.fr
-
Marseille, Франция
- Рекрутинг
- APHM La Timone Service de Maladies infectieuses
-
Контакт:
- Nadim CASSIR, MD
- Электронная почта: nadimshams.cassir@ap-hm.fr
-
Главный следователь:
- Nadim CASSIR, MD
-
Paris, Франция, 75012
- Рекрутинг
- Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP)
-
Контакт:
- Paul MCLELLAN, MD
- Номер телефона: +33 01 49 28 20 00
- Электронная почта: Paul.mclellan@aphp.fr
-
Главный следователь:
- Paul MCLELLAN, MD
-
Saint-Etienne, Франция, 42100
- Рекрутинг
- Service d'infectiologie - Hôpital Nord / CHU Saint Etienne
-
Контакт:
- Elisabeth BOTHELO-NEVERS, Pr
- Номер телефона: +33 04 77 12 77 89
- Электронная почта: elisabeth.botelho-nevers@chu-st-etienne.fr
-
Главный следователь:
- Elisabeth BOTHELO-NEVERS, Pr
-
Toulouse, Франция, 31059
- Рекрутинг
- Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse
-
Главный следователь:
- Laurent ALRIC, Pr
-
Контакт:
- Laurent ALRIC, Pr
- Номер телефона: 05 61 32 37 54
- Электронная почта: Alric.l@chu-toulouse.fr
-
Valence, Франция, 26000
- Рекрутинг
- Service de Maladies Infectieuses - CH de Valence
-
Контакт:
- Amélie DUREAULT, MD
- Номер телефона: +33 04 75 75 75 71
- Электронная почта: adureault@ch-valence.fr
-
Главный следователь:
- Amélie DUREAULT, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Adult patient ≥18 years of age
-
≥3rd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in stool by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI or 2nd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in the stools by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI with at least one of the following risk factors:
- Age ≥70 years
- Chronic renal failure (haemodialysis or GFR<60ml/min
- History of severe or severe-complicated CDI (excluding current episode) according to ESCMID 2021 criteria
- ≥3 CDI in the last 12 months (including current episode)
- CDI associated with care defined as CDI occurring during hospitalisation (<3 months)
-
On current or planned vancomycin treatment per os
-
Patient able to give free, informed and written consent
-
Enrolled in compulsory national social security scheme
Exclusion Criteria:
- Currently participating or has participated in a study with an investigational compound or device within 3 months prior to the first dose of the study intervention.
- Severe C. difficile infection severe (defined by the presence of a white blood cell count >15×10⁹ cells/L or a body temperature >38.5°C or >50% increase in the patient's baseline creatinine related to CDI at the time of V1) and/or complicated (defined by any of the factors attributed to current Clostridioides difficile infection (CDI): hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, intestinal perforation or any fulminant course of the disease)
- Refractory C. difficile infection defined as lack of response to well-conducted per os vancomycin or fidaxomicin treatment with ≥3 liquid stools per day after ≥5 days of treatment
- Cirrhosis with Child C score
- Hospitalization in continuing care unit or intensive care unit
- Personal history of gastrointestinal resection other than appendectomy (gastrectomy, esophagectomy, colonic or small bowel resection, short small bowel syndrome).
- Personal history of gastrointestinal resection resulting in chronic diarrhea (>3 loose stools per day)
- Inflammatory bowel disease
- Proven uncontrolled celiac disease
- Current stoma (ileostomy or colostomy) or within the last 6 months, or any other intra-abdominal surgery within the 3 months prior to treatment
- major surgery or trauma ≤ 4 weeks before the start of treatment or, if > 4 weeks ago, with an unresolved healing process that could affect the assessment or safety of the study treatment.
- Antibiotic therapy in progress or planned during the study for an infection other than CDI
- Surgery scheduled during the study requiring perioperative antibiotics.
- -Women without contraception*, pregnant or breastfeeding women
- History of hypersensitivity to EXL01 and/or to any of its excipients (D-mannitol, sucrose, maltodextrin, L-cysteine, L-cysteine hydrochloride, magnesium stearate and hydroxypropylmethylcellulose), and/or to soy or soy-containing products.
- History of hypersensitivity to vancomycin as mentioned in local prescribing information.
- Personal history of fecal microbiota transplantation < 6 months
- Persons deprived of liberty by judicial or administrative decision
- Adults under legal protection or unable to give consent
- Swallowing disorders making oral treatment impossible
- Participation in another interventional study within 3 months prior to inclusion. (Patients who have entered the follow-up phase of an interventional study may participate provided that more than 3 months have elapsed since the last intervention).
- Expected life expectancy of less than 6 months
- Presents a known psychiatric disorder that would interfere with adequate cooperation with study requirements.
- Regular use of illicit or recreational drugs that may interfere with the administration of the medication or the interpretation of the data
- History of chronic diarrhea (> 3 watery stools per day for > 4 weeks) not related to gastrointestinal infection.
- Clinically significant medical or surgical condition not mentioned in the above criteria which, in the opinion of the investigator, could interfere with the administration of study drug, the interpretation of study safety or efficacy data, or compromise the safety or well-being of the subject.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Часть A (открытая этикетка EXL01)
|
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
|
|
Экспериментальный: Часть Б (EXL01)
|
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
|
|
Плацебо Компаратор: Часть Б (Плацебо)
|
Following a at least 10-days vancomycin treatment: Oral placebo including:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events
Временное ограничение: at Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I The primary endpoint is the occurrence of serious adverse events (CTCAE grade≥3) during treatment and follow-up and discontinuation of treatment due to adverse events attributed to treatment |
at Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Временное ограничение: at Week 8
|
Phase II The primary endpoint is the proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of CDI-specific treatment. |
at Week 8
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Временное ограничение: at Week 8
|
Phase I Proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of specific treatment for CDI. |
at Week 8
|
|
Evaluation of the safety and tolerability profile of oral EXL01
Временное ограничение: at Week 2, Week 4, Week 8, Week 16
|
Phase II Occurrence of adverse events (CTCAE grade≥3) during treatment and follow-up, and discontinuation of treatment due to adverse events |
at Week 2, Week 4, Week 8, Week 16
|
|
Number of stools per day over the past 24 hours
Временное ограничение: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Временное ограничение: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Digestive symptoms are measured at each visit using the stool calendar |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Временное ограничение: at Week 8, Week 16
|
Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ) |
at Week 8, Week 16
|
|
Number of stools per day over the past 24 hours
Временное ограничение: at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Временное ограничение: at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Digestive symptoms are measured at each visit using the stool calendar |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Временное ограничение: at Week 8, Week 16
|
Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ) |
at Week 8, Week 16
|
|
Assessment of patient quality of life during treatment and follow-up
Временное ограничение: At Week 8 and Week 16
|
Phases I and II Patient quality of life at W8 and M4 measured by a validated digestive disease quality of life questionnaire (GIQLI) |
At Week 8 and Week 16
|
|
Assessment of recurrence of C. difficile infection
Временное ограничение: At Week 16
|
Phases I and II percentage of patients with recurrence of C. difficile infection at M4 |
At Week 16
|
|
Evaluation of the presence of EXL01 in the fecal microbiota
Временное ограничение: At Week 8
|
Phases I and II Level of F. prausnitzii (qPCR) in stool at W8 versus W0 |
At Week 8
|
|
Assessment of EXL01 persistence in the intestinal microbiota
Временное ограничение: At Week 0 and Week 16
|
Phases I and II Level of F. prausnitzii (qPCR) in stool at M4 versus W0 |
At Week 0 and Week 16
|
|
16S rRNA sequencing or shotgun
Временное ограничение: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Gut microbiota composition at each visit |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
16S rRNA sequencing or shotgun
Временное ограничение: at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Gut microbiota composition at each visit |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Временное ограничение: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Временное ограничение: at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Assessment of recurrences of C. difficile infection requiring hospitalization
Временное ограничение: At Week 8
|
phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at W8 |
At Week 8
|
|
Assessment of recurrences of C. difficile infection requiring hospitalization
Временное ограничение: at Week 16
|
phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at M4 |
at Week 16
|
|
Assessment of recurrences of C. difficile infection requiring surgery
Временное ограничение: at Week 8
|
phases I and II phases I and II percentage of patients with a recurrence of C. difficile infection requiring surgery at W8 |
at Week 8
|
|
Assessment of recurrences of C. difficile infection requiring surgery
Временное ограничение: at Week 16
|
phases I and II percentage of patients with recurrent C. difficile infection requiring surgery at M4 |
at Week 16
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Nicolas BENECH, MD, Hospices Civils de Lyon
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 69HCL22_0980
- 2023-506232-32-00 (Другой идентификатор: EU CT Number)
- 2023 (Грант/контракт NIH США)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .